John D. Davis, Regeneron
personal info
John is currently Vice President and head of Clinical Pharmacology at Regeneron Pharmaceuticals in Tarrytown. NY. He trained as a pharmacist in Nottingham, UK and received his PhD from the University of Manchester, UK. His thesis was entitled ‘Pharmacokinetic drug-drug interactions – fluoroquinolones and theophylline”. After initially joining the pharmaceutical industry as a pharmacokineticist working for a CRO, he subsequently worked at Pfizer’s Sandwich laboratories for 15 years, where he eventually became Executive Director and site head for Research Clinical Pharmacology. In 2011 he relocated to California to join Genentech’s Clinical Pharmacology group. He moved to the East coast to lead Regeneron’s Clinical Pharmacology department at the end of 2014, where he has built a strong team of around 40 Clinical Pharmacologists and Pharmacometricians. John led the Clinical Pharmacology support for the initial submissions for Dupixent®; he and his team have also supported the approvals for Libtayo®, Kevzara®, Praluent®, Evkeeza®, Inmazeb®, Regen-Cov®, Veopoz® and Eylea HD®. He has published ~90 papers in the area of clinical pharmacology and PK/PD.
John is a Fellow of the American College of Clinical Pharmacology (ACCP), was the joint program chair for the ACCP meeting in San Francisco, 2015 and is a past-chair of the Biologics community of the American Society of Clinical Pharmacology & Therapeutics.